Is MSI Testing Using NGS Data Accurate?
US FDA approves treatment for cancers with high microsatellite instability (MSI-H) highlight the importance of MSI testing in cancer treatment ; more and more companies adopting to use NGS data for MSI assessment, and the biggest benefit of NGS-based MS
SG MSL Team of ACT Genomics 2020-10-13
Ovarian Cancer Patient: Ms. Chang
While fighting ovarian cancer for 18 years, Ms. Chang underwent several rounds of chemotherapy and surgery. At her last check-up, her cancer was found to have metastasized. She was at the point of accepting her fate when her attending doctor recommended genomic profiling, which led to a treatment recommendation that had not previously been considered.
Squamous Cell Skin Cancer Patient: Ms. Chen
The family members of 87-year-old Ms. Chen were reluctant that she be made to endure another surgery when her cancer relapsed owing to her age and effects of previous surgeries. Genomic profiling was then explored with her doctor to identify if she might be a candidate of immunotherapy. Fortunately, she is.
Low-dose trastuzumab deruxtecan (T-DXd) demonstrated a clinical meaningful response in the subsequent treatment of HER2-mutated NSCLC with reduced toxicity
In this phase II Destiny-Lung02 trial, patients received lower dose (5.4 mg/kg) of trastuzumab deruxtecan (T-DXd) presented a lower toxicity without compromising efficacy. This result supported the FDA approval for T-DXd in NSCLC HER2-mut treatment.
Milademetan, an oral small molecule inhibitor of the MDM2-p53 complex showed early activity in TP53-WT and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2)
The preliminary data of the MANTRA-2 trial demonstrated that milademetan monotherapy had potent efficacy in TP53-WT and MDM2-amplified solid tumors with acceptable AE profiles.
Biomarker analysis of the BEACON study revealed acquired resistant mechanisms in the BRAF V600E-mut mCRC patients
The analysis of paired patients’ ctDNA in the BEACON study showed KRAS, NRAS, and MAP2K1 mutations and MET amplifications were the dominant resistant mechanism in BRAF-V600E mCRC patients treated with cetuximab + encorafenib +/- binimetinib. MAP2K1 mutations were more frequently seen in the cetuximab + encorafenib treatment groups.
A New HER2 Bispecific Antibody-drug Conjugate Demonstrates Potential in Treating HER2 Positive Solid Tumors
Abstract: Antibody-drug conjugate (ADC) is a rapidly developing field in the war against cancers. In recently published data from the 2022 ESMO congress, a HER2 bispecific ADC, zanidatamab zovodotin (ZW49), reveals its anti-tumor ability across cancer types. Although needed to be further evaluated, ZW49 might be a potential selection for treating HER2-positive solid cancer.
What are the benefits of genetic testing for cancer?
ACT Genomics received the 2021 Frost & Sullivan Best Practices Award in Asia-pacific Clinical Oncology Next-generation Sequencing Workflow Solutions Product Leadership.